10 Biggest Price Target Changes For Monday
Wells Fargo cut the price target on Gilead Sciences, Inc. (NASDAQ: GILD) from $70 to $63. Gilead Sciences shares rose 0.4% to $59.91 in pre-market trading.
HC Wainwright & Co. Maintains Buy on Eton Pharmaceuticals, Lowers Price Target to $11
HC Wainwright & Co. analyst Raghuram Selvaraju maintains Eton Pharmaceuticals (NASDAQ:ETON) with a Buy and lowers the price target from $14 to $11.
Eton Pharmaceuticals Q4 EPS $0.04 Up From $(0.32) YoY, Sales $6.1M
Eton Pharmaceuticals (NASDAQ:ETON) reported quarterly earnings of $0.04 per share. This is a 112.5 percent increase over losses of $(0.32) per share from the same period last year.
The Daily Biotech Pulse: Pfizer-BioNTech Apply For Authorization Of 3rd Booster Shot, Sanofi-Seagen Strike Cancer Therapy Pact, Iovance Gets Nod For Cancer Study
Here's a roundup of top developments in the biotech space over the last 24 hours.
Earnings Scheduled For March 16, 2022
Companies Reporting Before The Bell
• Ideanomics (NASDAQ:IDEX) is likely to report quarterly loss at $0.05 per share on revenue of $33.20 million.
The Week Ahead In Biotech (March 13-19): Bristol-Myers Squibb’s Melanoma Drug Decision, Multiple Conference Presentations And Earnings Dominate Proceedings
Biotech stocks pulled back for a second week running, as the Ukraine war cast its cloud on the broader market. Dwindling earnings news flow and company-specific developments served as catalysts during the week.
Eton Pharma Shares Quiet As FDA.gov AccessData Site Shows Co.’s New Drug Application For Hydrocortisone At Differing Milligrams Now Listed As FDA Approved Drugs
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=213876
The Week Ahead In Biotech (Jan 23-29): Roche, Azurity FDA Decisions, J&J, Vertex Earnings, Samsara Vision IPO And More
Biotech stocks pulled back yet again during the week ending Jan. 21, with the sector retreating along with the broader market. The news flow tapered off following the frenetic pace of the week that encompassed the JPM Healthcare conference.
Attention Biotech Investors: Mark Your Calendar For January PDUFA Dates
Regulatory decisions by the U.S. Food and Drug Administration in December turned out to be mostly positive. Among the treatment options that were greenlighted in the month were two new molecular entities.